Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia

In a phase IV trial, 84 patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Martner, Anna, Rydström, Anna, Riise, Rebecca E, Aurelius, Johan, Anderson, Harald, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760300/
https://www.ncbi.nlm.nih.gov/pubmed/26942055
http://dx.doi.org/10.1080/2162402X.2015.1041701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760300/
https://www.ncbi.nlm.nih.gov/pubmed/26942055
http://dx.doi.org/10.1080/2162402X.2015.1041701

Ejemplares similares